Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06294847

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

Led by Hopital Foch · Updated on 2025-05-14

120

Participants Needed

2

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of ursodeoxycholic acid (UDCA) as a supportive treatment to improve visual recovery after surgery for extended rhegmatogenous retinal detachment (RRD) involving two or more quadrants, with macula off for seven days or less. The study focuses on pseudophakic or aphakic patients who are scheduled for vitrectomy and gas tamponade surgery. The goal is to compare visual acuity improvements three months after surgery between patients receiving UDCA and those receiving a placebo. The trial enrolls 120 patients randomized into two groups. The experimental group receives oral UDCA, starting with a single dose of 10 mg/kg within 24 hours before surgery, then continuing with 10 mg/kg daily in two doses for 30 days. The control group receives a matching placebo on the same schedule. Both treatments are given alongside the standard surgical procedure involving vitrectomy and gas tamponade. Participants will be followed for six months with multiple assessments, including visual acuity tests at various timepoints up to 180 days, imaging such as optical coherence tomography (OCT), automated microperimetry, and adaptive optics to examine retinal cells. Blood tests monitor liver function, and questionnaires evaluate vision-related quality of life. Researchers will track adverse events and analyze correlations between molecular markers and ocular outcomes to assess the treatment's impact and safety.

CONDITIONS

Brief Title

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 years or older
  • Scheduled for vitrectomy surgery
  • Pseudophakic or aphakic patients
  • Rhegmatogenous retinal detachment involving 2 or more quadrants
  • Macula off for 7 days or less before symptoms started
  • Signed informed consent
  • Affiliated with a health insurance plan
Not Eligible

You will not qualify if you...

  • Previous vitrectomy surgery for retinal detachment
  • Presence of vitreous hemorrhage or other retinal diseases
  • Monophthalmic patients (only one eye)
  • Women of childbearing age without effective contraception
  • Pregnant or breastfeeding women
  • Hypersensitivity to UDCA or its components
  • Peptic ulcers or liver diseases
  • Infections or inflammation of gallbladder or bile ducts
  • Gallstones or obstruction of bile ducts
  • Severe pancreatic disorders
  • Intestinal diseases affecting bile acid circulation
  • Use of certain interacting medications
  • Rare hereditary metabolic diseases
  • Participation in other interventional trials with prohibited drugs
  • Patients under protective custody

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day 0

Participants undergo retinal detachment surgery and receive a single dose of study medication or placebo orally within 24 hours before the surgical intervention.

1 visit (in-person)

Treatment

Duration - 30 days

Participants take daily doses of the study medication or placebo orally in two divided doses for 30 days following surgery.

Visits on Day 7 and Day 30 (in-person)

Post-operative Follow-up

Duration - 6 months

Participants are monitored with assessments of visual acuity, retinal imaging, and quality of life questionnaires up to 6 months after surgery.

Multiple visits at 1, 3, and 6 months post-surgery

Trial Site Locations

Total: 2 locations

1

Hôpital Cochin

Paris, France, 75014

Actively Recruiting

2

Hôpital Foch

Suresnes, France, 92150

Actively Recruiting

Loading map...

Research Team

B

BEHAR COHEN Francine

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Determination of Feasibility of Intraoperative Spectral Doma...

Retinal Diseases

Actively Recruiting

1 location

High Resolution and High Speed Multimodal Ophthalmic Imaging

Retinitis Pigmentosa

Actively Recruiting

1 location

Intraoperative OCT Guidance of Intraocular Surgery to Evalua...

Macular Holes

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here